FreeCME

Emerging Treatment Strategies in the Treatment of Cancer for Practicing Physicians and Healthcare Professionals

This webcast is jointly provided by A. Webb Roberts Center for CME of Baylor Health Care System and CancerNet.

For more information visit: www.cancernetus.net

Grantors:

Eisai, Inc.
Onyx Pharmaceuticals, Inc., a subsidiary of Amgen, Inc.
Millennium Pharmaceuticals, Inc.
Genomic Health
Novartis Pharmaceuticals Corporation

Release date: Sept. 16, 2015

Valid through: Sept. 16, 2016

Specialty: Hematology/Oncology

Media: Internet

Target Audience

This webcast is directed primarily to hematologists/oncologists, radiation oncologists, surgical oncologists, pathologists, researchers, pharmacists, registered nurses, physician assistants, nurse practitioners and fellows in training interested in new developments for treatment of selected solid tumors and hematological malignancies. No specific skill or knowledge other than a basic training in hematology/ oncology is required for successful participation in this activity.

Statement of Need / Program Overview

This webcast is intended to improve care of patients with selected solid tumors and hematological malignancies by accelerating adoption of new guidelines and evidence-based practice change.  In addition to chemotherapy and targeted therapy of lung and breast cancers, this symposium will focus on individualized treatment options. In-depth discussion of novel agents at various stages of clinical development will be given significant focus. This enduring online activity is designed to provide clinical decision-making strategies for integration of novel therapeutic options.

This program consists of 5 continuing education activites.

Click the links below to review the activity launch pages containing full disclosure information.

Module 1 — 1.25 AMA PRA Category 1 Credits

Faculty

John V. Heymach, MD, PhD, Professor, Department of Thoracic/Head and Neck Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX

Jennifer Litton, MD, Associate Professor, Department of Breast Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX

Module 2 — 1.5 AMA PRA Category 1 Credits

Faculty

Christopher Logothetis, MD, Professor and Chair, Department of Genitourinary Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX

Scott Kopetz, MD, PhD, Associate Professor, Department of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX

Module 3 — 1.25 AMA PRA Category 1 Credits

Faculty

Nathan H. Fowler, MD, Associate Professor, Department of Lymphoma/Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX

Jason Westin, MD, Assistant Professor, Department of Lymphoma/Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX

Module 4 — 1.25 AMA PRA Category 1 Credits

Faculty

Michael Davies, MD, PhD, Associate Professor, Department of Melanoma Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX

Merrill Kies, MD, Professor of Medicine, Deputy Division for MDAnderson Cancer Network, Divison of Cancer Medicine, Houston, TX

Module 5 — 1.5 AMA PRA Category 1 Credits

Faculty

Elizabet Manasanch, MD, Assistant Professor, Department of Lymphoma/Myeloma, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX

David Hui, MD, Assistant Professor, Department of Palliative Care and Rehabilitation Medicine, Division of Cancer Medicine, University of Texas MD Anderson Cancer Center, Houston, TX